Collectively, our study revealed that MIB2 promoted the occurrence of lung cancer by regulating cell cycle, which may help to promote the development of new diagnostic or therapeutic biomarker to improve the prognosis of patients with NSCLC. This evidence concerns the gene MIB2 and lung carcinoma.